NasdaqGM:URGN

Stock Analysis Report

Executive Summary

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies.

Snowflake

Fundamentals

Flawless balance sheet with high growth potential.

Share Price & News

How has UroGen Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: URGN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

7.7%

URGN

2.5%

US Biotechs

0.9%

US Market


1 Year Return

-43.6%

URGN

10.8%

US Biotechs

16.8%

US Market

Return vs Industry: URGN underperformed the US Biotechs industry which returned 10.8% over the past year.

Return vs Market: URGN underperformed the US Market which returned 16.8% over the past year.


Shareholder returns

URGNIndustryMarket
7 Day7.7%2.5%0.9%
30 Day27.0%11.8%4.5%
90 Day-11.1%7.6%6.2%
1 Year-43.6%-43.6%11.8%10.8%19.4%16.8%
3 Yearn/a18.6%14.8%47.5%38.0%
5 Yearn/a5.8%0.8%62.0%44.1%

Price Volatility Vs. Market

How volatile is UroGen Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is UroGen Pharma undervalued compared to its fair value and its price relative to the market?

2.8x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate URGN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate URGN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: URGN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: URGN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate URGN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: URGN is good value based on its PB Ratio (2.8x) compared to the US Biotechs industry average (2.9x).


Next Steps

Future Growth

How is UroGen Pharma forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

62.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: URGN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).

Earnings vs Market: URGN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: URGN's is expected to become profitable in the next 3 years.

Revenue vs Market: URGN's revenue (68.1% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: URGN's revenue (68.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: URGN is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has UroGen Pharma performed over the past 5 years?

-57.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: URGN has high quality earnings.

Growing Profit Margin: URGN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: URGN is unprofitable, and losses have increased over the past 5 years at a rate of -57.8% per year.

Accelerating Growth: Unable to compare URGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: URGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (86.5%).


Return on Equity

High ROE: URGN has a negative Return on Equity (-42.62%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is UroGen Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: URGN's short term assets ($159.9M) exceeds its short term liabilities ($14.1M)

Long Term Liabilities: URGN's short term assets ($159.9M) exceeds its long term liabilities (1.7M)


Debt to Equity History and Analysis

Debt Level: URGN is debt free.

Reducing Debt: URGN has not had any debt for past 5 years.


Balance Sheet

Inventory Level: URGN has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if URGN's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: URGN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: URGN has sufficient cash runway for 1.821845 years if free cash flow continues to reduce at historical rates of -90.5% each year.


Next Steps

Dividend

What is UroGen Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate URGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate URGN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if URGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if URGN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of URGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of UroGen Pharma's salary, the management and board of directors tenure and is there insider trading?

1.3yrs

Average management tenure


CEO

Liz Barrett (57yo)

0.8yrs

Tenure

0

Ms. Elizabeth A. Barrett, also known as Liz, has been President, Chief Executive Officer and Director of UroGen Pharma Ltd. since January 3, 2019. She served as Chief Executive Officer of Novartis Oncology ...


Management Age and Tenure

1.3yrs

Average Tenure

55yo

Average Age

Experienced Management: URGN's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Age and Tenure

2.6yrs

Average Tenure

63yo

Average Age

Experienced Board: URGN's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: URGN insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$40,24818 Nov 19
Elizabeth Barrett
EntityIndividual
Role
Chief Executive Officer
President
Shares1,548
Max PriceUS$26.00
BuyUS$10,06622 Mar 19
Mark Schoenberg
EntityIndividual
Role
Senior Key Executive
Chief Medical Officer
Shares272
Max PriceUS$37.01
SellUS$35,39808 Mar 19
Mark Schoenberg
EntityIndividual
Role
Senior Key Executive
Chief Medical Officer
Shares949
Max PriceUS$37.30

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25.4%.


Management Team

  • Ron Bentsur (53yo)

    • Tenure: 0.8yrs
    • Compensation: US$5.95m
  • Gary Titus (59yo)

    Consultant

    • Tenure: 1.4yrs
    • Compensation: US$3.49m
  • Stephen Mullennix

    Chief Operating Officer

    • Tenure: 1.8yrs
    • Compensation: US$4.31m
  • Mark Schoenberg (61yo)

    Chief Medical Officer

    • Tenure: 1.9yrs
    • Compensation: US$300.00k
  • Peter Pfreundschuh (50yo)

    CFO & Secretary

    • Tenure: 1.3yrs
    • Compensation: US$2.49m
  • Liz Barrett (57yo)

    President

    • Tenure: 0.8yrs
  • Sari Prutchi-Sagiv

    Marketing Director

    • Tenure: 0yrs
  • Gil Hakim (49yo)

    Consultant

    • Tenure: 1.3yrs
    • Compensation: US$3.86m
  • Marina Konorty

    SVP of Research & Development and Head of Israel Operations

    • Tenure: 0yrs
  • Kate Bechtold

    Director of Corporate Communications & Investor Relations

    • Tenure: 1.8yrs

Board Members

  • Kate Falberg (58yo)

    Independent Director

    • Tenure: 2.6yrs
    • Compensation: US$540.33k
  • Fred Cohen (63yo)

    Independent Director

    • Tenure: 2.5yrs
    • Compensation: US$525.33k
  • Cindy Butitta (65yo)

    Independent Director

    • Tenure: 2.1yrs
    • Compensation: US$540.96k
  • Stuart Holden (76yo)

    Independent Director

    • Tenure: 3.9yrs
    • Compensation: US$527.83k
  • Arie Belldegrun (70yo)

    Chairman of the Board

    • Tenure: 16.9yrs
    • Compensation: US$1.98m
  • Ran Nussbaum (46yo)

    Independent Director

    • Tenure: 6.5yrs
    • Compensation: US$525.41k
  • Jack Baniel

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Liz Barrett (57yo)

    President

    • Tenure: 0.8yrs
  • Herbert Lepor

    Chairman of Scientific Advisory Board

    • Tenure: 0yrs
  • Fred Witjes

    Member of Scientific Advisory Board

    • Tenure: 0yrs

Company Information

UroGen Pharma Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: UroGen Pharma Ltd.
  • Ticker: URGN
  • Exchange: NasdaqGM
  • Founded: 2004
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$590.995m
  • Shares outstanding: 20.98m
  • Website: https://www.urogen.com

Number of Employees


Location

  • UroGen Pharma Ltd.
  • 499 Park Avenue
  • New York
  • New York
  • 10014
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
URGNNasdaqGM (Nasdaq Global Market)YesOrdinary SharesUSUSDMay 2017
UR8DB (Deutsche Boerse AG)YesOrdinary SharesDEEURMay 2017
0XODLSE (London Stock Exchange)YesOrdinary SharesGBUSDMay 2017

Biography

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company’s lead product candidates, UGN-101 and UGN-102 are proprietary  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/20 00:42
End of Day Share Price2019/11/19 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.